Drug releasing coatings for medical devices

• US 9,757,544 B2
• Filed: 03/11/2016
• Issued: 09/12/2017
• Est. Priority Date: 11/20/2006
• Status: Active Grant

• Current Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Original Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Inventors: Wang, Lixiao
• Primary Examiner(s): ZISKA, SUZANNE E
• Application Number:
  US15/067,739
• Publication Number:
  US 20160250387A1
• Time in Patent Office: 550 Days
• CPC Class Codes: A61F 2/844 folded prior to deployment
• CPC Class Codes: A61F 2/958 Inflatable balloons for placing stents or stent-grafts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/428 Vitamins, e.g. tocopherol, riboflavin
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 29/08 Materials for coatings
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/08 Materials for coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 2025/105 having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00

Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.

Claims

1. A medical device for delivering a therapeutic agent to a tissue, the medical device comprising a dried coating layer overlying an exterior surface of the medical device, the dried coating layer comprising a hydrophobic therapeutic agent and a first additive, and a second additive, wherein:

the hydrophobic therapeutic agent is a water-insoluble drug chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof; and

the first additive is selected from the group consisting of PEG sorbitan monolaurates, PEG sorbitan monooleates, and combinations thereof; and

the second additive is selected from the group consisting of sorbitol, sorbitan, xylitol, gluconolactone, and combinations thereof.

2. The medical device of claim 1, wherein the dried coating layer further comprises an antioxidant comprising propyl gallate.

3. The medical device of claim 1, wherein:

the first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof.

4. The medical device of claim 1, wherein:

the first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof; and

the second additive is selected from the group consisting of sorbitol, gluconolactone, and combinations thereof.

5. The medical device of claim 1, wherein:

the first additive is PEG-20 sorbitan monolaurate or PEG-20 sorbitan monooleate; and

the second additive is selected from the group consisting of sorbitol, xylitol, gluconolactone, and combinations thereof.

6. The medical device of claim 1, wherein the tissue includes tissue of one of coronary vasculature, peripheral vasculature, cerebral vasculature, esophagus, airways, sinus, trachea, colon, biliary tract, urinary tract, prostate, or brain passages.

7. The medical device of claim 1, wherein the medical device is one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, or a laser catheter.

8. The medical device of claim 1, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof.

9. The medical device of claim 1, wherein:

the medical device is a balloon catheter;

the hydrophobic therapeutic agent is paclitaxel; and

the dried coating layer further comprises an antioxidant comprising propyl gallate.

10. The medical device of claim 9, wherein the balloon catheter is a cutting balloon catheter or a scoring balloon catheter.

18. The medical device of claim 1, further comprising a top layer overlying a surface of the dried coating layer overlying the exterior surface of the medical device to reduce loss of the hydrophobic therapeutic agent during transit through a body to the tissue.

11. A medical device for delivering a therapeutic agent to a tissue, the medical device comprising a dried coating layer overlying an exterior surface of the medical device, the dried coating layer consisting essentially of a hydrophobic therapeutic agent and a combination of a water-soluble first additive and a water-soluble second additive, wherein:

the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof;

the water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof; and

the water-soluble second additive is selected from the group consisting of sorbitol, xylitol, gluconolactone, and combinations thereof.

12. The medical device of claim 11, wherein the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles.

13. The medical device of claim 11, wherein:

the water-soluble first additive is PEG-20 sorbitan monolaurate; and

the water-soluble second additive is gluconolactone.

14. The medical device of claim 11, wherein:

the water-soluble first additive is PEG-20 sorbitan monolaurate; and

the water-soluble second additive is sorbitol or xylitol.

15. The medical device of claim 11, wherein:

the water-soluble first additive is PEG-20 sorbitan monooleate; and

the water-soluble second additive is gluconolactone.

16. The medical device of claim 11, wherein:

the water-soluble first additive is PEG-20 sorbitan monooleate; and

the water-soluble second additive is sorbitol or xylitol.

17. The medical device of claim 11, wherein:

the water-soluble first additive is PEG-20 sorbitan monolaurate; and

the water-soluble second additive is lactobionic acid.

19. The medical device of claim 11, wherein the medical device is one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, or a laser catheter.

20. The medical device of claim 11, wherein the coating layer consists of the hydrophobic therapeutic agent and the combination of the water-soluble first additive and the water-soluble second additive.